or Try an Advanced Search...

    Technical Analysis for NKTX - Nkarta, Inc.

    Grade Last Price % Change Price Change
    D 6.87 0.73% 0.05
    NKTX closed up 0.73 percent on Friday, April 26, 2024, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: May 9
    *** please verify all earnings dates ***
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Down Down
    Historical NKTX trend table...
    Date Alert Name Type % Chg
    Slingshot Bearish Bearish Swing Setup 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Hammer Candlestick Bullish 0.73%
    Wide Bands Range Expansion 0.73%
    Oversold Stochastic Weakness 0.73%
    Wide Bands Range Expansion -4.18%
    Oversold Stochastic Weakness -4.18%
    Wide Bands Range Expansion -9.13%
    Oversold Stochastic Weakness -9.13%
    Older End-of-Day Signals for NKTX ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 16 hours ago
    Down 3% about 16 hours ago
    Down 2 % about 17 hours ago
    Hammer Candlestick Entry about 17 hours ago
    Rose Above Previous Day's High about 17 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    NKTX Chart by TradingView
    Basic chart:

    Profile

    Nkarta, Inc., a biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its co-lead product candidates are NKX101, a pre-clinical product that enhances the power of innate NK biology to detect and kill cancerous cells; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded in 2015 and is headquartered in South San Francisco, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Cancer Biology Immune System Immunotherapy Cancer Treatment Tumor Lymphoma Virotherapy Gene Therapy Chimeric Antigen Receptor T Cell Natural Killer Cell Therapies For Cancer Chimeric Antigen Receptor Antigen CD19 Tumor Cell

    Is NKTX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Mar 25 Nkarta: NK Cell Therapy Advancement On Two Fronts
    Mar 25 Why Nkarta Stock Just Boomeranged Following A Massive Dive On Friday
    Mar 25 Nkarta announces pricing of stock offering to raise $240.1M
    Mar 25 Nkarta Announces Pricing of $240 Million Underwritten Offering
    Mar 23 Nkarta Inc (NKTX) Posts Full Year 2023 Financial Results: A Focus on NKX019 and Pipeline Realignment
    Mar 22 Why Top 1% Biotech Stock Nkarta Just Plummeted, Undercutting Its 50-Day Line
    Mar 22 These Analysts Revise Their Forecasts On Nkarta After Q4 Results
    Mar 21 Nkarta GAAP EPS of -$0.57 beats by $0.03
    Mar 21 Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
    Mar 19 3 Overlooked Stocks Ready to Capture the Market by Storm
    See more NKTX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 16.24
    52 Week Low 1.28
    Average Volume 1,037,529
    200-Day Moving Average 5.35
    50-Day Moving Average 10.42
    20-Day Moving Average 8.37
    10-Day Moving Average 7.53
    Average True Range 0.88
    RSI (14) 33.33
    ADX 37.66
    +DI 12.18
    -DI 32.22
    Chandelier Exit (Long, 3 ATRs) 9.21
    Chandelier Exit (Short, 3 ATRs) 9.10
    Upper Bollinger Bands 10.49
    Lower Bollinger Band 6.26
    Percent B (%b) 0.14
    BandWidth 50.55
    MACD Line -1.00
    MACD Signal Line -0.91
    MACD Histogram -0.0849
    Fundamentals Value
    Market Cap 337.13 Million
    Num Shares 49.1 Million
    EPS -2.50
    Price-to-Earnings (P/E) Ratio -2.75
    Price-to-Sales 1000000.00
    Price-to-Book 1.84
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 7.80
    Resistance 3 (R3) 7.79 7.46 7.65
    Resistance 2 (R2) 7.46 7.23 7.47 7.59
    Resistance 1 (R1) 7.17 7.08 7.32 7.18 7.54
    Pivot Point 6.84 6.84 6.92 6.85 6.84
    Support 1 (S1) 6.55 6.61 6.70 6.56 6.20
    Support 2 (S2) 6.22 6.46 6.23 6.15
    Support 3 (S3) 5.93 6.22 6.10
    Support 4 (S4) 5.94